Meer over Cholest Control

Cholest Control is een natuurlijk voedingsupplement dat zonder voorschrift verkrijgbaar is en zowel policosanol als fytosterolen (plantenbestanddelen die ook verwerkt worden in cholesterolverlagende margrines) bevat.

Het is waarschijnlijk één van de gemakkelijkste en effectiefste manieren om je cholesterolniveau onder controle te houden.

Dit voedingssupplement bestaat voor 100% uit natuurlijke bestanddelen en de capsules zijn klein gehouden, zodat iedereen ze makkelijk kan innemen.

... met Cholest Control krijg je dagelijks de optimale hoeveelheden binnen

De meeste mensen denken dat hoe meer ze van een bepaalde stof nemen, hoe meer effect ze heeft.

Maar dat is niet altijd waar. Sterker nog. Teveel van éénder welke stof innemen kan een omgekeerd effect op je lichaam hebben!

En precies daarom is het zo belangrijk om niet zomaar éénder welk supplement in te nemen.  Enkel een optimale samenstelling geeft je de garantie dat je cholesterol op een compleet natuurlijke, veilige en effectieve manier onder controle blijft.

Het enige wat JIJ moet doen, is dagelijks 2 capsules met wat water innemen. Reeds na 30 tot 40 dagen zal het effect op je cholesterolniveaus merkbaar zijn.

Je goede HDL-cholesterol verhoogt (wat goed is!) terwijl je slechte LDL-cholesterol sterk vermindert.

4 redenen om Cholest Control meteen in huis te halen

De bijwerkingen van traditionele cholesterolverlagende medicijnen beroven je van een gelukkiger, gezonder en energieker leven. Hevige spierpijnen, vermoeidheid, duizeligheid… je kent het vast wel.

Nu kan je jouw cholesterolspiegel onder controle houden met 2 uiterst veilige, natuurlijke en effectieve supplementen. Zonder verdere bijwerkingen, zodat je opnieuw kan genieten van het leven waar je recht op hebt!

Waarom zou je nog één dag langer de kleine en grote lichamelijke ongemakken tolereren? Ik geef je welgeteld vier goede redenen om Cholest Control meteen in huis te halen:

1. Werking wetenschappelijk onderbouwd

Onderaan deze website vind je referenties naar 86 verschillende wetenschappelijke studies die aantonen dat zowel policosanol als fytosterolen, de twee bestanddelen van Cholest Control, bijzonder effectief zijn in het verlagen en controleren van het cholesterolgehalte in je lichaam. 

2. Optimale samenstelling

Cholest Control geeft je precies de dagelijkse hoeveelheid natuurlijke supplementen die je lichaam nodig heeft om het cholesterolgehalte in je lichaam permanent te controleren.

3. 100% veilig

Cholest Control bestaat uit volledig natuurlijke bestanddelen en beschikt over de nodige goedkeuringen van de Federale OverheidsDienst (FOD) Volksgezondheid onder het nummer NUT/PL 1047/1.

Het product voldoet aan de strengste normen op gebied van productie en gebruikte ingrediënten, wat een garantie is voor de kwaliteit van onze producten.

4. Geen bijwerkingen aangetoond

Aangezien Cholest Control bestaat uit natuurlijke plantenextracten, treden er geen bijwerkingen op. Hetgeen ook nog eens bevestigd wordt in de 86 verschillende wetenschappelijke studies die je hier beneden terugvindt.

Een gelukkiger, gezonder en energieker leven...voor minder dan 96 cent per dag!

Je weet vast wel hoeveel de cholesterolverlagende medicijnen met alle bijwerkingen kosten.

Dit 100% natuurlijk bestanddeel kost je minder dan 96 eurocent per dag. 

Gelieve er echter rekening mee te houden dat we de huidige, lage prijzen niet kunnen garanderen in de toekomst. Policosanol wordt ontgonnen uit rijst en de prijs van deze grondstof is de laatste maanden verdubbeld op de wereldmarkt.

Onze accountant dringt er op aan dat we de prijs verhogen maar voorlopig houden we dit nog even af. Maar ik weet niet hoe lang we je dit uitzonderlijk product nog kunnen aanbieden tegen deze absurd lage prijs.



REFERENTIES EN GEPUBLICIEERDE WETENSCHAPPELIJKE STUDIES IVM POLICOSANOL EN FYTOSTEROLEN
National Cholesterol Education Program Expert Panel. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106(25):3143-421.

Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280(18):1569-75.

MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med 2002; 35(2):166-73.

Gylling H, Miettinen TA. Cholesterol reduction by different plant stanol mixtures and with variable fat intake. Metabolism 1999;48(5):575-80.

Plat J, Mensink RP. Vegetable oil-based versus wood-based stanol ester mixtures: effects on serum lipids and hemostatic factors in non-hypercholesterolemic subjects. Atherosclerosis 2000;148(1):101-12.

Hallikainen MA, Uusitupa MI. Effects of 2 low-fat stanol ester-containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects. Eur J Clin Nutr 1999;69(3):403-10.

Hallikainen MA, Sarkkinen ES, Gylling H, Erkkila AT, Uusitupa MI. Comparison of the effects of plant sterol ester and plant stanol ester-enriched margarines in lowering serum cholesterol concentrations in hypercholesterolaemic subjects on a low-fat diet. Eur J Clin Nutr 2000;54(9):715-25.

Law M. Plant sterol and stanol margarines and health. BMJ 2000;320(7238):861-4.

Gouni-Berthold I, Berthold HK. Policosanol: clinical pharmacology and therapeutic significance of a new lipid-lowering agent. Am Heart J 2002;143(2):356-65.

Janikula M. Policosanol: a new treatment for cardiovascular disease? Altern Med Rev 2002;7(3):203-17.

Crespo N, Alvarez R, Mas R, Illnait J, Fernandez L, Fernandez JC. Effects of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholes-terolemia: a pilot study. Curr Ther Res Clin Exp 1997;58(1): 44-51.

Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Fernandez JC. Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: a randomized, double-blind, placebo-controlled study. Curr Ther Res Clin Exp 2001;62(3):194-208.

Pons P, Rodriguez M, Robaina C, et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment. Int J Clin Pharmacol Res 1994;14(1):27-33.

Aneiros E, Calderon B, Mas R, et al. Effect of successive dose increases of policosanol on the lipid profile and tolerability of treatment. Curr Ther Res Clin Exp 1993;54(3):304-12.

Castano G, Mas R, Fernandez L, Illnait J, Gamez R, Alvarez E. Effects of policosanol 20 versus 40 mg/day in the treatment of patients with type II hypercholesterolemia: a 6-month double-blind study. Int J Clin Pharmacol Res 2001;21(1): 43-57.

Canetti M, Moreira M, Illnait J, et al. One-year study of the effect of policosanol on lipid profile in patients with type II hypercholesterolemia. Adv Ther 1995;12(4):245-54.

Castano G, Mas R, Nodarse M, Illnait J, Fernandez L, Fernandez JC. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res Clin Exp 1995;56(3): 296-304.

Mirkin A, Mas R, Martinto M, et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res 2001;21(1):31-41.

Castano G, Mas R, Fernandez L, et al. Effects of policosanol on postmenopausal women with type II hypercholesterolemia. Gynecol Endocrinol 2000;14(3):187-95.

Mas R, Castano G, Illnait J, et al. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther 1999;65(4):439-47.

Castano G, Mas R, Fernandez JC, Illnait J, Fernandez L, Alvarez E. Effects of policosanol in older patients with type II hypercholesterolemia and high coronary risk. J Gerontol A Biol Sci Med Sci 2001;56(3):M186-92.

Castano G, Menendez R, Mas R, et al. Effects of D-003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy volunteers. Clin Drug Invest 2003;23(3):193-203.

Canetti M, Moreira M, Mas R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res 1995; 15(4):159-65.

Pons P, Rodriguez M, Mas R, et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1994;55(9):1084-92.

Castano G, Canetti M, Moreira M, et al. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: a 12-month study. Curr Ther Res Clin Exp 1995;56(8):819-28.

Castano G, Mas R, Fernandez JC, Illnait J. Comparative effects of two once-daily regimens of policosanol in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1997; 58(3):154-62.

Torres O, Agramonte AJ, Illnait J, Mas FR, Fernandez L, Fernandez JC. Treatment of hypercholesterolemia in NIDDM with policosanol. Diabetes Care 1995;18(3):393-7.

Mas R, Castano G, Fernandez L, Illnait J, Fernandez J, Alvarez E. Effects of policosanol on lipid profile and cardiac events in older hypercholesterolaemic patients with coronary disease. Clin Drug Invest 2001;21(7):485-97.

Aneiros E, Mas R, Calderon B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1995; 56(2):176-82.

Castano G, Mas R, Fernandez JC, Fernandez L, Illnait J, Lopez E. Effects of policosanol on older patients with hypertension and type II hypercholesterolaemia. Drugs R D 2002;3(3):159-72.

Zardoya R, Tula L, Castano G, et al. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function. Curr Ther Res Clin Exp 1996;57(7):568-77.

Castano G, Tula L, Canetti M, et al. Effects of policosanol in hypertensive patients with type II hypercholesterolemia. Curr Ther Res Clin Exp 1996;57(9):691-9.

Menendez R, Mas R, Amor AM, Fernandez JC, Gonzalez RM. Effects of policosanol on the susceptibility of low-density lipoprotein isolated from hypercholesterolemic patients at high coronary risk to in vitro copper-mediated lipid peroxidation: a randomized, double-blind pilot study. Curr Ther Res Clin Exp 2000;61(9):609-20.

Menendez R, Mas R, Amor AM, et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 2000;50(3):255-62.

Pons P, Mas R, Illnait J, et al. Efficacy and safety of policosanol in patients with primary hypercholesterolemia. Curr Ther Res Clin Exp 1992;52(4):507-13.

Arruzazabala ML, Molina V, Mas R, et al. Antiplatelet effects of policosanol (20 and 40 mg/day) in healthy volunteers and dyslipidaemic patients. Clin Exp Pharmacol Physiol 2002;29(10):891-7.

Batista J, Stusser R, Penichet M, Uguet E. Doppler-ultrasound pilot-study of the effects of long-term policosanol therapy on carotid-vertebral atherosclerosis. Curr Ther Res Clin Exp 1995;56(9):906-14.

Hernandez F, Illnait J, Mas R, et al. Effect of policosanol on serum lipids and lipoproteins in healthy volunteers. Curr Ther Res Clin Exp 1992;51(4):568-75.

Batista JF, Stusser RJ, Padron R, Sosa F, Pereztol O, Perez B. Functional improvement in coronary artery disease after 20 months of lipid-lowering therapy with policosanol. Adv Ther 1996;13(3):137-48.

Davidson MH, Maki KC, Umporowicz DM, et al. Safety and tolerability of esterified phytosterols administered in reduced-fat spread and salad dressing to healthy adult men and women. J Am Coll Nutr 2001;20(4):307-19.

Miettinen TA, Puska P, Gylling H, Vanhanen H, Vartiainen E. Reduction of serum cholesterol with sitostanol-ester margarine in a mildly hypercholesterolemic population. N Engl J Med 1995;333(20):1308-12.

Homma Y, Ikeda I, Ishikawa T, Tateno M, Sugano M, Nakamura H. Decrease in plasma low-density lipoprotein cholesterol, apolipoprotein B, cholesteryl ester transfer protein, and oxidized low-density lipoprotein by plant stanol ester-containing spread: a randomized, placebo-controlled trial. Nutrition 2003;19(4):369-74.

Tikkanen MJ, Hogstrom P, Tuomilehto J, Keinanen-Kiukaanniemi S, Sundvall J, Karppanen H. Effect of a diet based on low-fat foods enriched with nonesterified plant sterols and mineral nutrients on serum cholesterol. Am J Cardiol 2001;88(10):1157-62.

Vanhanen HT, Kajander J, Lehtovirta H, Miettinen TA. Serum levels, absorption efficiency, faecal elimination and synthesis of cholesterol during increasing doses of dietary sitostanol esters in hypercholesterolaemic subjects. Clin Sci (Lond) 1994; 87(1):61-7.

Temme EH, Van Hoydonck PG, Schouten EG, Kesteloot H. Effects of a plant sterol-enriched spread on serum lipids and lipoproteins in mildly hypercholesterolaemic subjects. Acta Cardiol 2002;57(2):111-15.

Gylling H, Radhakrishnan R, Miettinen TA. Reduction of serum cholesterol in postmenopausal women with previous myocardial infarction and cholesterol malabsorption induced by dietary sitostanol ester margarine: women and dietary sitostanol. Circulation 1997;96(12):4226-31.

Cleghorn CL, Skeaff CM, Mann J, Chisholm A. Plant sterol-enriched spread enhances the cholesterol-lowering potential of a fat-reduced diet. Eur J Clin Nutr 2003;57(1):170-6.

Lottenberg AM, Nunes VS, Nakandakare ER, et al. The human cholesteryl ester transfer protein i405v polymorphism is associated with plasma cholesterol concentration and its reduction by dietary phytosterol esters. J Nutr 2003; 133(6):1800-5.

Mensink RP, Ebbing S, Lindhout M, Plat J, van Heugten MM. Effects of plant stanol esters supplied in low-fat yoghurt on serum lipids and lipoproteins, non-cholesterol sterols and fat soluble antioxidant concentrations. Atherosclerosis 2002;160(1):205-13.

Spilburg CA, Goldberg AC, McGill JB, et al. Fat-free foods supplemented with soy stanol-lecithin powder reduce cholesterol absorption and LDL cholesterol. J Am Diet Assoc 2003;103(5):577-81.

Blomqvist SM, Jauhiainen M, Vantol A, et al. Effect of sitostanol ester on composition and size distribution of low-density and high-density-lipoprotein. Nutr Metab Cardiovasc Dis 1993;3(4):158-64.

Vanhanen HT, Blomqvist S, Ehnholm C, et al. Serum cholesterol, cholesterol precursors, and plant sterols in hypercholesterolemic subjects with different apoE phenotypes during dietary sitostanol ester treatment. J Lipid Res 1993;34(9):1535-44.

Maki KC, Davidson MH, Umporowicz DM, et al. Lipid responses to plant-sterol-enriched reduced-fat spreads incorporated into a national cholesterol education program step 1 diet. Am J Clin Nutr 2001;74(1):33-43.

Simons LA. Additive effect of plant sterol-ester margarine and cerivastatin in lowering low-density lipoprotein cholesterol in primary hypercholesterolemia. Am J Cardiol 2002;90(7): 737-40.

De Graaf J, Sauvage Nolting PR, Van Dam M, et al. Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels. Br J Nutr 2002;88(5):479-88.

Matvienko OA, Lewis DS, Swanson M, et al. A single daily dose of soybean phytosterols in ground beef decreases serum total cholesterol and LDL cholesterol in young, mildly hypercholesterolemic men. Am J Clin Nutr 2002;76(1):57-64.

Andersson A, Karlstrom B, Mohsen R, Vessby B. Cholesterol-lowering effects of a stanol ester-containing low-fat margarine used in conjunction with a strict lipid-lowering diet. Eur Heart J 1999;1(suppl)(S):S80-90.

Jones PJ, Ntanios FY, Raeini-Sarjaz M, Vanstone CA. Cholesterol-lowering efficacy of a sitostanol-containing phytosterol mixture with a prudent diet in hyperlipidemic men. Am J Clin Nutr 1999;69(6):1144-50.

Lee YM, Haastert B, Scherbaum W, Hauner H. A phytosterol-enriched spread improves the lipid profile of subjects with type 2 diabetes mellitus: a randomized controlled trial under free-living conditions. Eur J Nutr 2003;42(2):111-17.

Williams CL, Bollella M, Strobino BA, Boccia L, Campanaro L. Lipid-lowering effects of a plant stanol ester spread in young children. Eur Heart J 1999;1(suppl):S96-103.

Second Joint Task Force of European and Other Societies. Prevention of coronary heart disease in clinical practice: recommendations of the second joint task force of European and other societies on coronary prevention. Eur Heart J 1998;19(10):1434-503.

Katan MB, Grundy SM, Jones P, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003;78(8):965-78.

Illingworth DR. An overview of lipid-lowering drugs. Drugs 1988;36(suppl 3):63-71.

Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: factors limiting achievement of lipid goals. Am J Med 1996;100(2):197-204.

Rader DJ. Therapy to reduce risk of coronary heart disease. Clin Cardiol 2003;26(1):2-8.

Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol 2000;35(3):640-6.

Heller FR, Desager JP, Harvengt C. Plasma lipid concentrations and lecithin:cholesterol acyltransferase activity in normolipidemic subjects given fenofibrate and colestipol. Metabolism 1981;30(1):67-71.

Anonymous. Physicians' desk reference, 57th ed. Montvale, NJ: Medical Economics, 2003.

Castano G, Mas R, Fernandez L, et al. Comparison of the efficacy and tolerability of policosanol with atorvastatin in elderly patients with type II hypercholesterolaemia. Drugs Aging 2003;20(2):153-63.

Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308 (6925):367-72.

Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. Circulation 1998;97(10):946-52.

Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B. Cerivastatin gender effect: sub-analyses of results from a multinational, randomised, double-blind study: cerivastatin study group. Curr Med Res Opin 2000;16(2):80-7.

Dawson PA, Rudel LL. Intestinal cholesterol absorption. Curr Opin Lipidol 1999;10(4):315-20.

Heinemann T, Axtmann G, von Bergmann K. Comparison of intestinal absorption of cholesterol with different plant sterols in man. Eur J Clin Invest 1993;23(12):827-31.

Lichtenstein AH, Deckelbaum RJ. American Heart Association science advisory: stanol/sterol ester-containing foods and blood cholesterol levels: a statement for healthcare professionals from the nutrition committee of the council on nutrition, physical activity, and metabolism of the American Heart Association. Circulation 2001;103(8):1177-9.

Blair SN, Capuzzi DM, Gottlieb SO, Nguyen T, Morgan JM, Cater NB. Incremental reduction of serum total cholesterol and low-density lipoprotein cholesterol with the addition of plant stanol ester-containing spread to statin therapy. Am J Cardiol 2000;86(1):46-52.

Wilt TJ, MacDonald R, Ishani A. b-Sitosterol for the treatment of benign prostatic hyperplasia: a systematic review. BJU Int 1999;83(9):976-83.

Ling WH, Jones PJ. Dietary phytosterols: a review of metabo-lism, benefits and side effects. Life Sci 1995;57(3):195-206.

Taylor JC, Rapport L, Lockwood GB. Octacosanol in human health. Nutrition 2003;19(2):192-5.

Mas R, Rivas P, Izquierdo JE, et al. Pharmacoepidemiologic study of policosanol. Curr Ther Res Clin Exp 1999;60(8) 458-67.

Ortensi G, Gladstein J, Valli H, Tesone PA. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res Clin Exp 1997;58(6): 390-401.

Prat H, Roman O, Pino E. Comparative effects of policosanol and two HMG-CoA reductase inhibitors on type II hypercholesterolemia. Rev Med Chil 1999;127(3):286-94.

Nikitin I, Slepchenko NV, Gratsianskii NA, et al. Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia. Ter Arkh 2000;72(12):7-10.

Denke MA. Lack of efficacy of low-dose sitostanol therapy as an adjunct to a cholesterol-lowering diet in men with moderate hypercholesterolemia. J Lipid Res 1995;61(2):392-6.

Jenkins DJ, Kendall CW, Marchie A, et al. Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003;290(4):502-10.

Abramowicz M, ed. Three new drugs for hyperlipidemia. Med Lett Drugs Ther 2003;45(1151):17-19.